Partnership combines Apexon's agentic AI platforms and cloud modernization tools with AWS infrastructure to accelerate AI deployment, clinical innovation, and digital transformation across healthcare and life sciences
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Clearing 19 biologics for Europe market
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Pharma powerhouse names Cecile Guegan interim finance chief
Bolstering neuroscience push with late-stage Tourette therapy
Subscribe To Our Newsletter & Stay Updated
